Insulet Corporation reports news on its Omnipod product platform for diabetes care, including the Omnipod Insulin Management System and Omnipod 5 Automated Insulin Delivery System. The company’s tubeless disposable Pods provide up to three days of insulin delivery, while Omnipod 5 integrates with continuous glucose monitors and can be controlled through a compatible smartphone in the U.S. or through the Omnipod 5 Controller.
Recurring Insulet developments include quarterly results, Omnipod revenue trends, sensor-connectivity updates, clinical evidence for automated insulin delivery, and research involving fully closed-loop systems for type 2 diabetes. Company updates also cover medical device corrections, product quality actions, executive appointments, conference presentations, and the use of Omnipod technology for non-insulin subcutaneous drug delivery.
Insulet Corporation (NASDAQ: PODD) will present at three virtual investor conferences: the Wells Fargo Healthcare Conference on September 9, the Morgan Stanley Global Healthcare Conference on September 10, and the Baird Global Healthcare Conference on September 15, 2021. Each presentation will be accessible via live webcasts, which will also have replays available afterwards. Insulet specializes in innovative diabetes management technology, specifically its Omnipod tubeless insulin delivery system, designed to simplify life for individuals with diabetes.
Insulet Corporation (NASDAQ: PODD) has received FDA clearance to use Eli Lilly's Lyumjev® (insulin lispro-aabc) with its Omnipod® Insulin Management System. Insulet is the only U.S. insulin pump manufacturer authorized for this use, enhancing flexibility for diabetes management. Lyumjev, a rapid-acting insulin, improves post-meal glucose control and is effective when delivered via continuous subcutaneous insulin infusion. This collaboration with Lilly aims to simplify diabetes care by providing more options for insulin administration.
Insulet Corporation (NASDAQ: PODD) announced the upcoming launch of the Omnipod DASH Insulin Management System in Australia at the Australasian Diabetes Congress. Orders are expected to be taken by the end of August. The Omnipod DASH is the first waterproof, tubeless insulin pump in Australia, designed to provide insulin therapy for up to 72 hours. This launch is part of Insulet’s global expansion strategy, which previously included markets in Europe and the Middle East. The new system aims to simplify diabetes management with its intuitive design and customer-centric business model.
Insulet Corporation (NASDAQ: PODD) reported Q2 2021 revenues of $263.2 million, a 16.3% increase from the prior year. Omnipod revenue reached $242.1 million with a 19.9% increase. U.S. Omnipod revenue was $150.5 million (up 16.8%), while international revenue hit $91.6 million (up 25.1%). Despite a gross margin rise to 69.4%, the company reported a net loss of $25.0 million due to a debt extinguishment loss. Adjusted EBITDA improved to $52.3 million. Insulet reaffirms its 2021 revenue guidance of 16%-20% growth.
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, will present at two virtual investor conferences. The Canaccord 41st Annual Growth Conference is scheduled for August 11, 2021, at 11:00 a.m. ET, followed by the UBS Genomics 2.0 and MedTech Innovations Summit on August 12, 2021, at 4:00 p.m. ET. Live audio webcasts can be accessed via investors.insulet.com, with replays available post-event. Insulet is dedicated to enhancing diabetes management through its innovative Omnipod Insulin Management System.
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, will release its financial results for Q2 2021 on August 5, 2021, after market close. A conference call is scheduled for the same day at 4:30 p.m. Eastern Time. The Omnipod Insulin Management System continues to innovate in diabetes management, providing up to three days of insulin delivery without the need for needles.
Insulet Corporation (NASDAQ: PODD) announced positive results from its pivotal trial for the Omnipod 5 Automated Insulin Delivery System, focusing on children aged 2 to 5.9 years with type 1 diabetes. The trial showed a reduction in HbA1c from 7.4% to 6.9% and increased time in range from 57.2% to 68.1%. Additionally, 100% of participants opted to continue using Omnipod 5 in a 12-month extension phase, indicating satisfaction. The results were shared at the American Diabetes Association's 81st Scientific Sessions.
Insulet Corporation (NASDAQ: PODD) announced its schedule for the American Diabetes Association's 81st Scientific Sessions from June 25-29, 2021, where it will present new clinical outcomes data on the Omnipod 5 Automated Insulin Delivery System. This includes findings from the pivotal trial for preschool children and results following transitions from multiple daily injections for patients aged 6 to 70. A total of eight presentations are planned. The Omnipod 5 has received breakthrough device designation from the FDA and is expected to launch in limited release in the latter half of 2021.
Insulet Corporation (NASDAQ: PODD) reported a strong financial performance for Q1 2021, with revenues of $252.3 million, marking a 27.4% increase from the previous year. Omnipod revenue contributed $233.2 million, up 22.9%. The gross margin improved to 66.4%, and operating income rose to $16.3 million. The company achieved a net loss of $0.0 million compared to a loss of $2.1 million in Q1 2020. Insulet is optimistic for 2021, raising revenue guidance to 16%-20%. They presented favorable data at ENDO 2021, indicating improved outcomes for users of the Omnipod 5 system.
Insulet Corporation (NASDAQ: PODD) will present at the virtual BofA Securities 2021 Health Care Conference on May 12, 2021, at 4:15 p.m. (ET). The company is a leader in tubeless insulin pump technology with its Omnipod® products, designed to enhance the lives of diabetes patients. Interested parties can listen to the presentation live via Insulet's investor page, where a replay will also be available afterward.
Insulet's innovative Omnipod system simplifies insulin delivery with a wearable, needle-free design, enhancing comfort for users.